Kazusa Genome Technologies

What Kazusa Genome Technologies does

Kazusa Genome Technologies (KGT) is the omics analysis services business line operated by Eurofins Genomics K.K. (ユーロフィンジェノミクス株式会社), a Japan-incorporated subsidiary of the global Eurofins Group, established in 2015 and headquartered in Kisarazu, Japan. The business provides commissioned analytical services across the omics stack: DIA-based proteomics (capable of identifying and comparatively quantifying up to 12,000 proteins from mammalian cultured cells), Seer-based serum/plasma proteomics (as Seer's first domestic agent in Japan), lipidome/metabolome analysis, integrated multi-omics combining transcriptomics and proteomics from a single sample, omics data analysis for drug target identification, next-generation sequencing (Illumina HiSeq/MiSeq), PacBio Sequel-based long-read sequencing, and single-cell analysis. All wet-lab work is conducted domestically within Japan at specialized research facilities, with proteomics run in partnership with Kazusa DNA Research Institute (かずさDNA研究所) using their independently optimized DIA proteomics platform and state-of-the-art mass spectrometers.

The unit serves two primary verticals: domestic Japanese research institutions (the primary segment) and pharmaceutical / drug-discovery companies (secondary), with use cases spanning disease mechanism analysis, biomarker discovery, and drug target identification. GTM is sales-led and direct: project-based commissioning via dedicated email ([email protected]) and phone (03-5492-7001), with no published pricing — all quotes are issued on request. The service catalog is marketed through the Eurofins Genomics Japan corporate website, with dedicated landing pages for each omics modality and bundling potential into Eurofins' adjacent Japan offerings (oligo synthesis, DNA sequencing, gene synthesis, antibody/peptide services). The founder and representative director is Akira Hasegawa.

Commercially, KGT operates as a business line inside Eurofins Genomics K.K., which is itself part of Eurofins Group, a multi-billion-euro international testing conglomerate. No standalone financials, funding rounds, headcount, or growth metrics are disclosed for KGT specifically. Revenue mechanics are professional-services-style: per-project contracted analytical work with expert consultation included, repeat engagement likely from academic core facilities and pharma biomarker groups. The principal commercial differentiators cited are domestic Japan execution, exclusive Seer access, the optimized DIA platform inherited from Kazusa DNA Research Institute, and integration with Eurofins' broader Japan channel.

Name

Kazusa Genome Technologies

Legal name

Eurofins Genomics K.K. (ユーロフィンジェノミクス株式会社)

Website

https://kazusagt.com

Company type

Private

Founded year

2015

Operating status

Operating

Short description

Kazusa Genome Technologies is the omics contract-research arm of Eurofins Genomics K.K. in Japan, providing DIA proteomics, Seer plasma proteomics, metabolomics, multi-omics, NGS, long-read, and single-cell analysis services to Japanese research institutions and pharmaceutical companies.

Ownership category

akta.pro rank

Product category

Genomics & Proteomics Analytical Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Genomics & Next-Generation Sequencing (NGS) Services (HLAGANAA), Transcriptomics & Gene Expression Profiling Services (HLAGANAE)

Keywords

• Omics analysis services
• Proteomics research
• Multi-omics solutions
• NGS sequencing services
• Lipidomics metabolomics

Headquarters

HQ city

Kisarazu

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Omics Analysis Contract Services: Commissioned omics analysis services provided to research institutions and pharmaceutical companies. Services are conducted domestically in Japan by specialized researchers with consulting and after-sale support included.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Kazusa Genome Technologies, operating under Eurofins Genomics K.K. in partnership with Kazusa DNA Research Institute, provides commissioned omics analysis services including DIA proteomics, lipidome/metabolome analysis, multi-omics (transcriptomics plus proteomics), NGS analysis, long-read sequencing (PacBio), and single-cell analysis. All services are conducted domestically in Japan by specialized researchers with consulting and after-sale follow-up support, targeting research institutions and pharmaceutical companies.

Product overview

Kazusa Genome Technologies, in partnership with Eurofins Genomics, provides a comprehensive suite of omics analysis services including proteomics, metabolomics/lipidomics, transcriptomics, and genomics. The core offerings comprise Seer analysis services for plasma proteomics, DIA proteomics capable of identifying up to 12,000 proteins, lipidome/metabolome analysis, multi-omics analysis combining transcriptomics and proteomics, omics data analysis for drug target identification, NGS analysis, long-read sequencing using PacBio technology, and single-cell analysis. All services are conducted domestically by specialized researchers with professional consulting and follow-up support.

Differentiator

Problem solved

Functional benefit

Products and services

• Seer Analysis Service
• Proteome Analysis
• Lipidome/Metabolome Analysis
• Multi-Omics Analysis
• Omics Data Analysis
• NGS Analysis
• Long-Read Sequencing Analysis
• Single Cell Analysis

Quantifiable outcome

• Identification and comparative quantification of up to 12,000 types of proteins from mammalian cultured cells

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered core.

• Kazusa DNA Research Institute (かずさDNA研究所)coreStrategic or Co-development PartnerKazusa DNA Research Institute conducts the proteomics analysis for KGT omics services. The institute has independently optimized DIA proteomics technology for analytical depth and quantification accuracy, enabling identification and comparative quantification of up to 12,000 proteins from mammalian cultured cells using state-of-the-art mass spectrometers.
• Seer (シーア)coreTechnology or IntegrationSeer is a globally recognized company in serum/plasma proteomics technology. Eurofins Genomics is the first domestic agent in Japan for Seer technology, offering advanced serum/plasma proteomics analysis services that represent an evolution from previous methods.

Scale indicators1 record

Recent moves4 records

Expansion highlights3 records

Broad incumbents

• BGI Genomics: BGI is a global genomics and multi-omics services company offering NGS, proteomics, and bioinformatics at very high scale. It is a relevant comparable for KGT's NGS and multi-omics contract research business, though it operates globally and at significantly larger scale.
• Bruker: Bruker is a major mass spectrometry and proteomics instrumentation and services provider (including timsTOF and DIA proteomics workflows). It is a broad incumbent comparable to KGT's DIA proteomics service line and could either partner with or compete against specialty omics service providers.
• Charles River Laboratories: Charles River is a large global CRO with growing capabilities in genomics, proteomics, and biomarker services for drug discovery. It is a broad incumbent that competes with KGT for pharma-sponsored omics work, especially in larger discovery and translational engagements.
• SCIEX: SCIEX (Danaher) supplies mass spectrometers and proteomics/metabolomics workflows used in omics contract services. It is a broad incumbent in the proteomics and metabolomics tooling stack underpinning KGT's services.

Emerging players

• PhycoBio: PhycoBio is a Japan-based omics and bioinformatics services company focused on metagenomics and microbiome analysis. It is an emerging player with partial overlap to KGT's omics service portfolio, particularly in microbiome/translational research applications.

Direct peers

• Macrogen: Macrogen is an Asia-based (Korea) genomics services company providing NGS, Sanger, and increasingly multi-omics services to global research customers. It is a direct comparable for KGT's genomics/omics CRO services, with similar target customers and a comparable scale.
• Takara Bio: Takara Bio is a Japan-based life sciences company offering reagents, gene synthesis, and omics-related services including NGS and single-cell analysis. It is a direct domestic Japanese peer for KGT's research services in the academic and pharma market.
• Novogene: Novogene is a leading global NGS and multi-omics contract research organization serving pharma and academic customers. It directly competes with KGT's NGS, long-read, single-cell, and bioinformatics offerings, especially for Japanese academic and pharma projects that can be sent overseas.
• Filgen: Filgen is a Japan-based life sciences distributor and service provider offering proteomics, metabolomics, and NGS analysis. It is a domestic Japanese peer for KGT's omics services, particularly in academic and pharma research accounts.

Regional players

• DNA Link: DNA Link is a Korea-based genomics and bioinformatics services company serving research and clinical customers in Asia. It is a regional comparable to KGT in NGS and multi-omics service delivery, though it primarily serves the Korean market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kazusa Genome Technologies